SanBio to Submit Additional Data to Obtain Approval for Lead Cell Therapy

To read the full story

• Sign In
• Subscribe

Related Article

• SanBio Sees Akuugo Expanding to 20-30 Treatment Centers
  June 11, 2026

• SanBio Debuts Akuugo Stem Cell Therapy for Traumatic Brain Injury
  May 22, 2026

• SanBio Targets Akuugo Shipments after May NHI Listing
  March 26, 2026

• SanBio Clears Hurdle for Akuugo Shipments, Heads to Reimbursement Talks
  December 10, 2025

• SanBio’s Akuugo Nears Shipment with MHLW Panel Backing; Sakigake Tag OK’ed for Bayer Gene Therapies
  October 17, 2025

• SanBio’s Akuugo Set for Re-Review on Oct. 16, Shipment Decision Nears
  October 3, 2025

• SanBio Eyes Akuugo Label Expansion Talks with PMDA in FY2026
  September 19, 2025

• SanBio Pushes Back Shipment Approval Timeline for Cell Therapy Akuugo
  June 26, 2025

• SanBio, Minaris Aim to Expand Global Reach of Akuugo
  June 20, 2025

• SanBio Inches Closer to Cell Therapy Shipment with Partial Change Filing
  June 13, 2025

• SanBio’s Cell Therapy Akuugo Scores Conditional Approval
  August 1, 2024

• SanBio Says Its Lead Cell Therapy Could Be Shipped from 2025 If All Goes Well
  June 21, 2024

• SanBio’s Lead Cell Therapy in Line for Conditional Nod but Can’t Be Shipped Until Comparability Is Confirmed
  June 20, 2024

• SanBio’s Lead Cell Therapy Up for Review Again on June 19
  June 14, 2024

• Japan Shelves Decision on SanBio’s Lead Cell Therapy on Quality Concerns
  March 26, 2024

• SanBio Chief Baffled by Planned Advisory Session over Lead Cell Therapy
  March 21, 2024

• Japan Panel to Discuss Fate of SanBio’s Sakigake Cell Therapy amid Stalled Review
  March 19, 2024

• Approval by January Unlikely for SanBio’s Lead Cell Therapy as Production Review Stalls
  October 21, 2022

• SanBio’s Sakigake Cell Therapy Finally Filed in Japan for Traumatic Brain Injury
  March 8, 2022

• Filing for SanBio’s Sakigake Cell Therapy for TBI Likely to Be Delayed
  December 16, 2020

• SanBio to Start Talks with PMDA over Late-Stage Study of SB623 in Ischemic, Hemorrhagic Strokes: COO
  September 17, 2020

• SanBio to Focus on Cell Therapy SB623 for Brain Injury, Stroke, Seeking Licensees for Other Indications
  July 16, 2020

• Sumitomo Dainippon Pulls Plug on SanBio’s Lead Cell Therapy
  December 16, 2019

• SanBio’s Lead Cell Therapy Rides High with FDA’s RMAT Designation for Traumatic Brain Injury
  September 20, 2019

• SanBio to Move Ahead with SB623 Development in Stroke after PII Miss: President
  March 26, 2019

• SanBio Vows to Continue Development of Stem Cell Therapy SB623 despite Setback: President
  February 25, 2019

• Stem Cell Therapy SB623 Misses Key Target in US PIIb Study for Stroke: SanBio, Sumitomo Dainippon
  January 30, 2019

• Sumitomo Dainippon, SanBio to Jointly Develop Cell Therapy Agent for Chronic Stroke in North America
  September 30, 2014